• Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

    On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College…

  • AASLD 2023: 17 Must-See Studies

    From November 10th to 14th, the annualHepatology Digest  conference, the American Association for the Study of Liver Diseases (AASLD) 2023 held in Boston, USA. This event gathers the latest academic developments, clinical research findings, and major academic presentations in the field of liver disease. The following is a summary of 17 highly anticipated studies scheduled…

  • Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab

    This 2023 ESMO Annual Meeting, in the field of gastric cancer, the global Phase III MATTERHORN study of the anti-PD-L1 antibody pembrolizumab in combination with the FLOT regimen for neoadjuvant treatment in resectable gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) was presented as a Late-breaking Abstract (LBA) with mid-term analysis results (Abstract No.: LBA73). The mid-term…

  • ESMO 2023 | Dr. Silvia Stacchiotti: Advancements and Challenges in Treating Metastatic Sarcoma

    Metastatic sarcoma presents a formidable challenge in the realm of cancer treatment. The sheer diversity of sarcoma subtypes and the necessity of tailoring treatments to each specific histology makes the quest for effective therapies all the more complex. In this article, we delve deeper into the current landscape of advancements and challenges in the treatment…

  • ESMO 2023 | Dr. Andrea Necchi: Advancements in Intravesical Delivery Systems for the Treatment of Bladder Cancer

    Bladder cancer presents a complex challenge that demands innovative approaches to treatment. In recent years, significant progress has been made in the development of intravesical delivery systems for targeted therapy in bladder cancer patients. This article aims to provide a comprehensive overview of the latest advancements in intravesical delivery systems, with a particular focus on…

  • ESMO 2023 | Dr. Ryan J. Sullivan: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?

    The landscape of advanced melanoma treatment has witnessed a remarkable transformation with the introduction of targeted therapies and immunotherapies. While immunotherapy has shown great promise in various cancer types, there exist specific scenarios where targeted therapy can outshine immunotherapy. In this article, we delve into the situations where targeted therapy may be the preferred choice…

  • ESMO 2023 | Dr. Henrik Grönberg: Outcome Adaptive Design and Biomarker-Based Treatment Selection

    Prostate cancer remains a significant global health concern, predominantly affecting men. In recent groundbreaking research led by Dr. Henrik Grönberg, a novel approach known as outcome adaptive design was implemented to revolutionize the assessment of different drugs simultaneously. This innovative study design incorporated the dynamic adjustment of randomization probabilities based on individual patient outcomes, enabling…

  • ESMO 2023 | Dr. Kjetil Boye: Emerging Therapeutic Strategies and Promising Drugs May Benefit Sarcoma Patients

    The field of sarcoma treatment is currently undergoing a remarkable transformation with the development of cutting-edge therapeutic strategies and promising drugs. This article aims to provide an in-depth overview of these emerging treatment options and highlight key findings from recent research, shedding light on the potential breakthroughs in sarcoma management.